Phases, active trials: Phase 1: 43, Phase 2: 97, Phase 3: 93, Other: 138
Novartis has a diversified late-stage pipeline spanning oncology, ophthalmology, cardiovascular, and immunology. Their radioligand therapy (RLT) franchise, anchored by Lutathera and Pluvicto (lutetium PSMA-617), has established Novartis as the leader in targeted radiotherapy for solid tumors. In breast cancer, Kisqali (ribociclib) continues expanding into new settings against CDK4/6 inhibitor competitors. Kymriah pioneered the CAR-T category, and Novartis continues investing in next-generation cell therapies. Their ophthalmology pipeline (Luxturna gene therapy, complement inhibitors for geographic atrophy) represents a major growth vector.
- Oncology (radioligand, CDK4/6, CAR-T)
- Ophthalmology / gene therapy
- Cardiovascular
- Immunology / inflammation
- Neuroscience
- Kisqali (ribociclib): HR+ breast cancer CDK4/6 inhibitor
- Pluvicto (lutetium-177 PSMA): metastatic prostate cancer
- Kymriah (tisagenlecleucel): CAR-T lymphoma/leukemia
- Cosentyx (secukinumab): IL-17A, psoriasis/ankylosing spondylitis
- Iptacopan: complement Factor B, IgA nephropathy
- Scemblix (asciminib): BCR-ABL1 CML
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| CAR-T Long Term Follow Up (LTFU) Study NCT02445222 | Primary completion moved at least 3 years 1 month later Enrollment reduced 21% | Recruiting |
30 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in… NCT06894511 | Oct 15, 2026 · Estimated | Phase 2 |
23 more on the Completions page. See the calendar →
Monitor the Novartis pipeline daily
Get a daily digest when Novartis registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Hidradenitis Suppurativa | 14 |
| Breast Cancer | 11 |
| Multiple Sclerosis | 10 |
| Chronic Spontaneous Urticaria | 9 |
| Relapsing Multiple Sclerosis | 8 |
| Atherosclerotic Cardiovascular Disease | 6 |
| Immunoglobulin A Nephropathy | 6 |
| Asthma | 5 |
Novartis regularly initiates combination trials for Kisqali and Pluvicto in new patient populations. Their radioligand therapy pipeline expansion, beyond PSMA into SSTR2 and other targets, is one of the most watched programs in oncology BD.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Novartis's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Novartis may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Novartis pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) NCT07357727 | Recruiting | Trial sites expanded: 118 → 125 locations | 2026-10-10 |
| An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone… NCT06991556 | Active, Not Recruiting | Completion pushed from Sep 4, 2035 to Oct 4, 2035 | 2026-10-10 |
| A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle… NCT06546670 | Recruiting | Trial sites expanded: 10 → 13 locations | 2026-10-10 |
| Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for… NCT05445843 | Active, Not Recruiting | Completion moved earlier from Dec 31, 2026 to Oct 28, 2026 | 2026-10-09 |
| Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in… NCT06813911 | Active, Not Recruiting | Final enrollment: 246 participants (planned 340) | 2026-10-08 |
Each trial page shows every change DataLookout has recorded for that trial.